肝硬化合并细菌感染的治疗策略

Treatment strategies of bacterial infection in liver cirrhosis

感染是肝硬化患者的常见并发症及主要死亡原因。近年来,人们逐渐认识到感染,尤其是自发性腹膜炎对肝硬化患者病程及预后有重要影响。及时有效的经验性抗感染治疗对肝硬化合并感染患者的治疗尤为关键,但由于多重耐药菌及广泛耐药菌的传播,肝硬化合并感染的治疗成为难点。随着研究的不断深入,肝硬化合并感染的发病机制逐渐明确,肠道微生态干预及免疫调节治疗等新型治疗手段已成为热点。为肝硬化合并感染患者制定有效的治疗方案是提高肝硬化患者生存率及生活质量的关键。

Infection is a common complication and leading cause of death in liver cirrhosis patients.In recent years,people gradually recognize the vital impact of infection,especially spontaneous bacterial peritonitis,on the course and prognosis of liver cirrhosis patients.Timely and effective empiric antibiotic therapy is particularly critical for the treatment of liver cirrhosis patients with bacterial infection.However,due to the spread of multidrug resistant bacteria and extensively drug-resistant bacteria,infection in cirrhosis has also become a difficult problem.At the same time,we have a clearer understanding on the pathogenesis of infection in cirrhosis.Novel therapeutic methods,such as intestinal microecological intervention and immunoregulatory therapy,have also become research hotspots recently.Establishing an effective treatment plan for liver cirrhosis patients with bacterial infections is the key to improve the survival rate and quality of life of these patients.